Journal article
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
Abstract
Interstitial lung diseases (ILD) encompasses a heterogeneous group of parenchymal lung diseases characterized by variable amounts of inflammation and fibrosis. The targeting of fibroblasts and myofibroblasts with antifibrotic treatments is a potential therapeutic target for these potentially fatal diseases. Treprostinil is unique among the prostacyclin mimetics in that it has distinct actions at additional prostaglandin receptors. Preclinical …
Authors
Kolb M; Orfanos SE; Lambers C; Flaherty K; Masters A; Lancaster L; Silverstein A; Nathan SD
Journal
Advances in Therapy, Vol. 39, No. 9, pp. 3881–3895
Publisher
Springer Nature
Publication Date
September 2022
DOI
10.1007/s12325-022-02229-8
ISSN
0741-238X